Navigation Links
AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
Date:9/25/2008

VIENNA, Austria, September 25 /PRNewswire/ -- The successful progress of several vaccine programmes run by AFFiRiS GmbH has prompted investor MIG AG to increase its investment in the company. It has set up two new funds - MIG 5 and MIG 7 - to give private investors in Germany and Austria the opportunity to invest in this promising biotech company. The company decided to take this step for two reasons. First, to ensure the early coverage of future capital demand for the continued successful development of vaccines against Alzheimer's disease and atherosclerosis and, second, the tremendous potential that the proprietary AFFITOME platform technology offers the global pharmaceutical market.

The investment group MIG-Fonds announced today that it has increased its investment in AFFiRiS by a further Euro 3 million. As a result, private investors now have another chance to share in the economic success of the biotech company via the MIG Fonds 5 and 7. This news is particularly relevant for private investors in Germany, who have immediate access to MIG 7. This provides investors with the opportunity to make a highly promising investment before the modified capital gains tax comes into force in Germany. Therefore, after a year's holding period, any later profits made from this investment will be tax free.

AFFiRiS will contribute to the success of these funds through its proprietary AFFITOME technology, which is based on the process of molecular mimicry. This technology enables the development of customized vaccines known as AFFITOPE. Dr. Walter Schmidt, co-founder and company CEO, explains the key to the company's AFFiRiS vaccine strategy: "Our patented AFFITOME technology enables scientists to create both molecules with very specific binding characteristics and molecules that differ in structure but exhibit identical binding characteristics. We are currently using these strengths in the development of vaccines against Alzheimer's disease. In the future,
'/>"/>

SOURCE AFFiRiS GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Gerresheimer Further Increases its Sales and Earnings Power
2. OncoGenex increases economic interest in lead cancer drug OGX-011
3. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
4. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
5. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
6. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
7. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
8. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
9. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
10. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
11. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... NEWTOWN, Pa. , June 2, 2015   ... services and technology provider, today announced that David ... has been named Executive Vice President and Chief Financial ... 8, 2015. Peters brings more than 25 ... in pharmaceutical services. "David has extensive and deep knowledge ...
(Date:6/2/2015)... , June 2, 2015  Alere Inc. ... rapid diagnostics, joined the White House Antibiotic Stewardship ... commitments to support and advance the President,s National ... commitments include a number of measurable goals and ... achieved, will help healthcare providers protect their patients ...
(Date:6/2/2015)... New Orleans, LA (PRWEB) June 02, 2015 ... of custom gene synthesis to improve protein expression, announced ... The board includes six executives and entrepreneurs with a ... and software industries. , The team includes: , ... Startup Fund: , Roussel has a background in technology ...
(Date:6/1/2015)... and RARITAN, N.J. , June ... (Janssen) announced data from the Phase 3 multicenter ... progression-free survival (PFS) with trabectedin (YONDELIS ® ) ... (LPS) or leiomyosarcoma (LMS) previously treated with an ... SAR3007 is the largest randomized Phase 3 study ...
Breaking Biology Technology:BioClinica Names David Peters New Chief Financial Officer 2Alere Announces Broad Initiatives to Help Combat Antibiotic Resistance during White House Antibiotic Stewardship Forum 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... BIOD ) today reported financial results for the ... Quarter Operating Highlights During Biodel,s third quarter of ... 1 testing of two new ultra-rapid-acting formulations of recombinant human ... at Oregon Health and Sciences University who have initiated a ...
... Calif. and TORONTO, Aug. 4, 2011 ... developing a first-in-class anti-apoptosis therapeutic protein known as ... www.generex.com ), a biotechnology company developing a buccal ... in a Phase III trial, today are making ...
... AMSTERDAM, The Netherlands, August 4, 2011 SynCo ... of biopharmaceuticals today announced that its aseptic filling facility is ... first drug product batches for its clients after the expansion ... of the Class A zone is an important milestone in ...
Cached Biology Technology:Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Third Quarter Fiscal Year 2011 Financial Results 6Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 2Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 3Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 4Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes 5SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2
(Date:5/18/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/14/2015)... 2015  Verificient Technologies, Inc., a technology ... remote proctoring, announced a new alliance partnership ... creator of the Canvas Learning Management System ... will benefit from the seamless integration of ... a fully integrated multifactor biometrics behavioral application, ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... Boulder, Colo., USA New GSA Bulletin articles cover wind ... on Kauai; new insights from the Petrified Forest, USA; a ... a new model for the development of Ries Crater Lake, ... large earthquakes in northern Fiordland, New Zealand; and the evolution ...
... research at the Institute of Food Research, has taken ... and drug companies worldwide. , IFR and the technology ... from the Biotechnology and Biological Sciences Research Council (BBSRC) ... and improve how well it simulates the release of ...
... surrounds the DNA of our cells could help develop treatments ... have discovered that the proteins within this coating known ... different organs of the body. This variation ... proteins in the protective seal to cause illness in some ...
Cached Biology News:Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 2Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 3Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 4Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 5Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 6Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 7Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 8Kauai, the Petrified Forest, Costa Rica, and more: New GSA Bulletin articles now online 9Commercial future for Model Gut 2Cell discovery could hold key to causes of inherited diseases 2
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
... while maintaining high cell viability , ... , Fast: less than one ... , Highly reproducible results from ... with the Bio-Rad Gene Pulser Xcell System ...
100 adhesive strips....
Request Info...
Biology Products: